Equities

OncoTherapy Science Inc

OncoTherapy Science Inc

Actions
  • Price (EUR)0.256
  • Today's Change0.00 / 0.00%
  • Shares traded280.00
  • 1 Year change+26.73%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments5281,1181,837
Total Receivables, Net189123400
Total Inventory74100231
Prepaid expenses9.101619
Other current assets, total1866114
Total current assets8181,4222,601
Property, plant & equipment, net000.02
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets508985
Total assets8671,5112,685
LIABILITIES
Accounts payable------
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total360609605
Total current liabilities360609605
Total long term debt10700
Total debt10700
Deferred income tax----0.34
Minority interest------
Other liabilities, total4747100
Total liabilities514656705
SHAREHOLDERS EQUITY
Common stock50789789
Additional paid-in capital26,32224,79424,794
Retained earnings (accumulated deficit)(26018)(24728)(23602)
Treasury stock - common0.00----
Unrealized gain (loss)------
Other equity, total0.000.000.00
Total equity3548551,980
Total liabilities & shareholders' equity8671,5112,685
Total common shares outstanding218193193
Treasury shares - common primary issue0.0000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.